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Summary Topoisomerase I inhibitors are interesting anti-cancer agents with a novel mechanism of action. We
performed a phase I study with intravenous GI147211, a new semisynthetic camptothecin analogue, using a
daily x 5 schedule administered every 3 weeks, to evaluate the side-effects and pharmacokinetics of the agent.
Patients with a histologically confirmed diagnosis of a solid tumour refractory to standard forms of therapy
were eligible for the study. GI147211 was given as a 30 min intravenous infusion daily for 5 consecutive days,
repeated every 3 weeks. In subsequent patient cohorts the dose was escalated from 0.3 to 1.5 mg m-2 day-'.
Pharmacokinetics analysis was performed on days 1 and 4 of the first course using a validated high-
performance liquid chromatographic assay and non-compartmental methods. A total of 19 patients were
entered into the study, one patient was not evaluable for toxicity because only one drug administration was
given. Eighteen patients received a total of 67 courses through four dose levels. The dose-limiting toxicities
were neutropenia and thrombocytopenia at the dose of 1.5 mg m-2 day-'. Nadirs occurred on day 15 and day
15 respectively. Other toxicities were mild and infrequent and included nausea/vomiting, headache and
alopecia. The maximal tolerated dose was 1.2 mg m-2 day-'. One partial response was observed in a patient
with colorectal cancer. The total plasma clearance was 999+ 184 ml min-1 (range 640-1329). The volume of
distribution was 190+46
1 m-2 and the terminal half-life was 3.7 + 1.2 h. The AUC increased linearly with the
administered dose. A steep and significant sigmoid relationship was established between the AUC and the per
cent decrease ofANC. GI147211 is a new topoisomerase I inhibitor that induced dose-limiting neutropenia and
thrombocytopenia in this phase I study. The recommended dose for phase II studies with this schedule is
1.2 mg m-2 x 5 every 3 weeks.
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GI147211, [7 -(methylpiperazinomethylene) - 10,11 -ethylene-
dioxy-20(S)] camptothecin dihydrochloride, is a water-soluble
semisynthetic analogue of camptothecin (CPT). Early clinical
trials with CPT in the late 1960s showed hints of activity of
this plant alkaloid in a variety of solid tumours (Gottlieb et
al., 1970; Muggia et al., 1972; Creaven et al., 1972). Its
further development was stopped because of unpredictable
and severe myelosuppression, gastrointestinal toxicity and
haemorrhagic cystitis.
In the late 1980s two discoveries brought about a renewal
of interest in CPT; firstly, topoisomerase I was identified as
the single cellular target of CPT (Hsiang et al., 1985; Hsiang
and Liu, 1988) and, secondly, an overexpression of
topoisomerase I was found in various tumour cell lines but
not in normal tissues (Giovanella et al., 1989; Hirabayaski et
al., 1992; Potmesil et al., 1988). Topoisomerase I is a nuclear
enzyme that resolves topological problems of the torsionally
strained (supercoiled) DNA (Slichenmyer et al., 1993). This is
achieved by forming a covalent adduct between topoisome-
rase I and the DNA, termed the cleavable complex. This
catalytic intermediate creates single-strand DNA breaks,
allowing the DNA molecule to rotate around the intact
DNA strand at the cleavage site, leading to a relaxation of
the DNA molecule and in this way replication, transcription
and other DNA functions can proceed. These enzyme-
bridged breaks are then resealed by topoisomerase I. CPT
stabilises the cleavable complexes, thereby preventing
resealing of single-strand DNA breaks in the presence of
the drug (Covey et al., 1989; D'Arpa and Liu, 1989; Eng et
al., 1988). Cytotoxicity is specific to the S-phase of the cell
cycle because the double-strand breaks that occur during this
phase are more difficult to repair in the presence of the drug
(Horwitz and Horwitz, 1973).
Recently, several semisynthetic CPT analogues (Creemers
et al., 1994; Potmesil, 1994) have been developed, aiming at
reduced toxicity and sustained or improved activity.
One of these analogues, G1147211, demonstrated signifi-
cant cytotoxicity against several xenografts of human cancers
including HT-29 and SW-48 colon, PC-3 prostate, MX-1
breast, H460 lung, SKOV3 ovarian and KB epidermoid
carcinomas (Emerson et al., 1993, 1994, 1995). The relative
effect on tumour growth was dose-schedule dependent with a
greater reduction in tumour volume achieved by prolonged
dosing. LDIo in mice was 75 mg m-2 (20 mg kg-') given as a
single bolus injection. Animal toxicology studies by the
intravenous route showed that myelosuppression was the
main toxicity and was dose-limiting.
We performed a phase I and pharmacological study with
intravenous GI147211 on a daily x 5 regimen, repeated every
3 weeks, in patients with solid tumours.
Patients and methods
Patient selection
Patients with a histologically confirmed diagnosis of a solid
tumour refractory to standard forms of therapy were eligible
for this study. Other eligibility criteria included: (1) age>, 18
years; (2) an Eastern Cooperative Oncology Group (ECOG)
performance status<2; (3) a predicted life expectancy of at
least 3 months; (4) no previous anti-cancer therapy
for at least 3 weeks (6 weeks for previous nitro-
soureas or mitomycin C); (5) adequate haemato-
poietic (WBC)3 x 109 -', ANC> 1.5 x 109 1-' and platelets
100 x 10 1-1), hepatic (bilirubin within normal limits, AST,
ALT and/or alkaline phosphatase<2.0 x normal), and renal
(serum creatinine< 130 imol 1-') functions. All patients gave
written informed consent.
Correspondence: CJH Gerrits, Department of Medical Oncology,
Rotterdam Cancer Institute, Groene Hilledijk 301, 3075 EA
Rotterdam, The Netherlands
Received 11 September 1995; accepted without revision; accepted 30
October 1995Treatment and dose escalation
In the published phase I studies (Rowinsky et al., 1992;
Verweij et al., 1993) using topotecan on a daily x 5 schedule,
the starting dose was 1/30th of the murine LD,0 level
because of the significant interspecies differences in toxicity.
By rough estimate the murine LDIo for G1147211 was
equivalent to topotecan. However, the in vitro and in vivo
pharmacology suggested that topotecan is 2.2-fold less
potent than G1147211 (15-16). Therefore it was felt that
a safe starting dose for GI147211 should be less than 1/30 of
the mouse LD,0; 0.3 mg m-2 day-' given as a 30 min
infusion for 5 consecutive days was selected. Courses were
to be repeated every 3 weeks as tolerated. Dose escalations
were based on the prior dose level toxicity. For example if
no toxicity was seen in the prior dose,< 100% dose
escalation was allowed. However, if toxicity was seen, a
dose escalation of 25-50%, which was determined by the
worst significant toxicity, was prescribed. At least three
patients were entered at each dose level. The maximum
tolerated dose (MTD) was defined as one dose level below
the dose that induced dose-limiting toxicities (DLTs), which
were defined as at least one of the following: (1)
ANC<0.5 x 109 1 1 or platelets<50 x 109 l-' for more than
5 days; (2) ANC<0.5 x 10 1-1 with fever requiring
parenteral antibiotics, and/or non-hematological toxi-
city ,CTC grade 3 in more than one-third of GI147211
naive patients (at least two of a maximum of six patients).
Intrapatient dose escalation was not performed.
GI147211 was supplied by Glaxo as a clear solution in
vials of 2.0 ml. The vials contained a mixture of 0.5 mg of
G1147211 and 100 mg of dextrose. The pH was adjusted to
3.5 with sodium hydroxide or hydrochloric acid. GI147211
was diluted in D5W. The infusion bag (GI147211 + D5W)
contained 100 ml exactly.
During the first course patients were hospitalised, all other
courses were given at the outpatient clinic.
Treatment assessment
Before therapy medical history was taken and complete
physical examination, complete blood cell (CBC) count,
serum chemistries including sodium, potassium, chloride,
bicarbonate, calcium, phosphorus, creatinine, urea, uric acid,
glucose, total protein, albumin, bilirubin, alkaline phospha-
tase, AST, ALT, were performed, as were urinalysis,
coagulation parameters (APTT, PT), electrocardiogram
(ECG) and chest radiograph. Weekly evaluations between
the courses included history, physical examination, toxicity
assessment according to the CTC criteria (National Cancer
Institute, 1988) and serum chemistries. CBC and urinalysis
were determined twice weekly. Tumour measurements were
performed after every two courses and evaluated according to
the WHO criteria for response (World Health Organization,
1979); patients were taken off protocol in case of disease
progression.
Pharmacokinetics
For pharmacokinetic analysis whole blood samples (7 ml) in
heparinised tubes were collected from an indwelling i.v. canula,
placed in the arm contralateral to that receiving the drug,
before infusion and at 15, 25, 45 min and 1, 1.5, 2, 4, 6, 8, 10,
12 h after the initiation ofthe infusion on days 1 and 4 of the
first course. Urine was collected within a 2 hour interval before
the dosing and over the intervals; 0-4, 4-8, 8-12 and 12-
24 h. Both blood and urine samples were analysed for the
lactone form using a validated chromatographic assay,
according to a method published by Stafford and St. Claire
(1995). The AUC was calculated using the trapezoidal method
with extrapolation of the curve to infinity on day 1 and
extrapolated to 24 h on day 4. The terminal half-life was
calculated asln2/1 where A is the elimination rate constant, the
total plasma clearance (Cl) as dose/AUC and the apparent
volume ofdistribution at steady state (Vd,,) as
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Sigma Plot for Windows (release 2.0, Jandel scientific) and
PCNONLIN (release 4.0, SCI software) were used for
pharmacological data analysis. The sigmoid Emax model (Hill
equation) was used to explore relationships between pharma-
cokinetic parameters and per cent decrease ANC and per cent
decrease thrombocytes. The Gauss-Newton algorithm was
used withoutweighing factor. The concentration ofthe drug in
the infusion bags was also quantitated by high-performance
liquid chromatography (HPLC).
Results
A total of 19 patients entered the study. Patient character-
istics are given in Table I. All patients were eligible but one
patient with NSCLC was considered not evaluable for
toxicity and response as the patient was taken off study
after the first drug administration, because of development of
broncho-oesophageal fistula. In total 18 patients were
evaluable for toxicity and response. The total number of
evaluable courses was 67. The median number of courses per
patient was four (range 4-10). Dose levels studied were 0.3,
0.6, 1.2 and 1.5 mg m-2 day '.
Hematological toxicity
Neutropenia and thrombocytopenia were the dose-limiting
toxicities of GI147211 on this schedule (Table II). No
myelotoxicity was observed at the first two dose levels. At
the third dose level (1.2 mg m 2 day -'), grade 3-4
neutropenia and thrombocytopenia were seen in 7/15 and
6/15 of the courses respectively. The median ANC nadir at
this dose level was 1.29 x 109 l-' (range 0.08-5.6), for
platelets it was 74x 109 11 (range 33-379). The median
duration of severe myelosuppression, expressed as the
number of days between the first occurrence of grade 3-4
toxicity and recovery to<grade 2 toxicity, was 10 days for
neutropenia and 7 days for thrombocytopenia (Table III). In
three of six patients first receiving 1.2 mg m-2 day -1, the
dose was subsequently reduced to 0.9 mg m-2 day -'; in two
of the patients because of slow recovery from myelosuppres-
sion (with retreatment being permitted on day 28 and day 35
respectively); and in one patient because of febrile
neutropenia with sepsis during the first course. At
1.5 mg m-2 day -' the dose-limiting toxicity was reached
(Figure 1). Grade 3-4 neutropenia was noted in 13/15
courses (86%). The median ANC nadir was 0.09 x 1091'
Table I Patient characterisitics
Number of patients
Sex (male/female)
Median age (range)
Median performance score (ECOG)
0
1
2
Prior therapy
Chemotherapy
Radiotherapy
Both
None
Tumour types
NSCLC
Colorectal cancer
Sarcoma
Unknown primary
Pancreatic cancer
Breast cancer
Mesothelioma
Oropharyngeal cancer
19
10/9
59 (34-74)
11
8
0
6
7
5
2
9
3
l
l
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Table H Haematological toxicity
Neutrophils
Dose (mgm-2 Number of Number of Leucocytes CTC grades Platelets
day) patients evaluable courses 1 2 3 4 1 2 3 4 1 2 3 4
0.3 3 10 0 0 0 0 0000 0 0 0 0
0.6 3 18 8 0 0 0 4 1 0 0 1 0 0 0
0.9 3 9 3 1 1 0 0 4 1 0 4 2 1 0
1.2 6 15 1 1 4 2 2 2 1 6 0 1 6 0
1.5 6 15 0 9 3 3 2 0 2 11 2 6 4 3
Table III Neutropenia and thrombocytopenia at the two highest dose levels
Median number ofdays Median day of Median number of
Median day of from grade 3-4 to occurrence of daysfrom grade 3-4
occurrence ofgrade recovery > grade 2 grade 3-4 to recovery > grade
3-4 thrombocytopenia Day nadir thrombocytopenia neutropenia Day nadir 2 neutropenia
1.2 mg -2 day- 15 (15-15)' 15 (10-19)a 7 (2-8)a 15 (10-19)b 22 (13-22)b 10 (1_10)b
1.5 mgm 2 day-' 15 (10-15)b 15 (13 15)b 8 (5-12)b 10 (5-25)c 15 (13-22)c 11 (4-25)c
an=6 bn=7. Cn= 13.
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0
2
z
4
3
2
0
en
4) +-a
a
I II
1 5 8 10 15 19 22
1 5 8 10 15
Time (days)
19 22
Figure 1 Comparison of the median ANC (a) and median
platelet (b) counts of all given courses at doses of 1.2 (-0-) and
1.5 (+) mgm-2day-l.
(range 0.01 - 1.7). The median number of days to recover
from grade 3 -4 neutropenia was 11 days (range 4 -25).
Three infectious complications were observed, two of them
were life-threatening septic complications caused by gram-
negative bacteria. In addition, thrombocytopenia grade 3-4
was seen in 7/15 courses (46%). At this dose of 1.5 mg
m-2 day-1 the median platelet nadir was 62 x 109 1-' (range
10-116). The recovery of grade 3-4 thrombocytopenia
occurred in 8 days (range 5-12). Thrombocytopenia was
complicated by gastrointestinal bleeding in two patients.
Anaemia occurred frequently but was never severe.
Regularly, subsequent courses had to be postponed, owing
to delayed recovery of myelosuppression. At the dose of
1.2 mg m-2 day -1 a treatment delay of 1 week was required
in four courses and a delay of 2 weeks was required in two
courses. At 1.5 mg m-2 day -1 a treatment delay of 1 week
was necessary in three courses and a delay of 2 weeks in two
courses.
Cumulative myelotoxicity was not observed. The pattern
of myelosuppression during the first course predicted the
pattern in all subsequent courses (Figure 2).
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Figure 2 Graph showing course ofANC (-El-) and platelets (+)
duringsubseq-%uentcrcles with GI147211 of patient 16 at the dose
of l.5mgm- day- .
Non-haematological toxicity
Overall, non-haematological toxicities were relatively mild.
Nausea and vomiting were not dose-related and occurred in
30 (44%) and 15 (22%) of the given courses respectively and
were never worse than grade 1-2. These symptoms were
present only during the periods of drug administration and
could easily be circumvented by the prophylactic use of
standard anti-emetics. Alopecia was dose related, alopecia
grade 1 was observed in three patients at the highest two dose
levels. Mild headache was not dose-dependent and occurred
in eight courses (12%). Prophylactic use ofanalgesics such as
paracetamol during the days of drug administration
prevented this symptom. No other toxicities were seen.
There was no diarrhoea, mucositis, liver or renal toxicity.
Pharmacokinetics and kinetic-dynamic relationships
Complete plasma sampling was obtained from all 18 patients
on days 1 and 4 during the first course.
The pharmacokinetic data are summarised in Tables IV, V
and VI. The AUC was linearly related to the dose (Figure 3).
Total plasma clearance, determined on day 1, was 1014+
177.0 ml min- m-2 (mean+s.d.), V&5 was 193+ 45.9 1 m-2
(mean+s.d.), t1/2 was 3.54+0.99 h (mean+s.d.) and mean
residence time (MRT) was 3.53+0.93 h (mean+s.d.).
Significant sigmoid relationships were observed between
the AUC on day 4 of treatment and the per cent decrease
ANC (Figure 4). No significant influence of pretreatment on
these relationships was observed (Figure 5).
The fraction of the drug excreted unchanged in the urine
(fe) on day 1 was 0.14+0.07 and the renal clearance was
140+74 ml min-' m-2 (Table IV).Responses One partial response was seen in a patient with
metastatic colorectal cancer. His tumour had previously been
shown to be resistant to 5-FU/folinic acid. The remission
achieved by G1147221 lasted 6 weeks. A minor response was
observed after two courses in a patient with liver metastasis
of a leiomyosarcoma of the stomach, previously progressive
after two courses of doxorubicin/ifosfamide. The patient
refused further treatment because the second course was
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complicated by a non-drug-related upper gastrointestinal
bleeding. Stable disease was seen in ten patients.
Discussion
The characterisation of the inhibition of topoisomerase I as
the mechanism of action of CPT has resulted in the
Table IV Pharmacokinetic data after i.v. administration of GI147211 on day 1 of the first course
Patient Dose AUCnf Cma tmx tl MRT Clearance Vds
number (mg m-2) Day (ng mrl h) (ng ml-) (h) (h) (h) (ml min m 2) (Im 2)
1 0.3 1 4.93 3.63 0.42 2.96 2.89 1014 161
2 0.3 1 4.04 4.27 0.42 1.99 1.66 1238 104
3 0.3 1 4.77 3.73 0.42 2.63 3.33 1048 194
Mean 4.58 3.88 0.42 2.52 2.63 1100 153
4 0.6 1 10.10 9.16 0.42 3.35 4.01 990 223
5 0.6 1 15.63 9.41 0.42 2.81 3.74 640 134
6 0.6 1 14.00 11.46 0.42 2.80 3.52 714 140
Mean 13.25 10.01 0.42 2.98 3.76 781 166
7 1.2 1 17.57 17.33 0.42 3.62 3.01 1138 189
8 1.2 1 24.95 11.97 0.42 4.04 5.18 802 237
9 1.2 1 16.70 15.99 0.42 2.54 2.94 1198 193
10 1.2 1 15.05 12.83 0.42 2.40 3.04 1329 223
11 1.2 1 19.86 14.11 0.25 5.10 3.98 1007 225
12 1.2 1 19.42 17.65 0.42 2.97 2.66 1030 149
Mean 18.93 14.98 0.39 3.45 3.47 1084 203
13 1.5 1 24.66 15.08 0.25 4.98 5.11 1014 296
14 1.5 1 - 27.48 0.42 - - - -
15 1.5 1 24.39 19.21 0.42 4.62 3.57 1025 204
16 1.5 1 23.32 19.53 0.25 4.37 3.32 1072 197
17 1.5 1 22.64 18.91 0.25 4.61 3.65 1104 225
18 1.5 1 28.37 15.90 0.75 4.42 3.78 881 186
Mean 24.68 19.35 0.39 4.60 3.89 1019 222
AUCinf, AUC after extrapolation to infinity; Cmax, maximal plasma concentration; tmax, time to maximal plasma concentration; ti, elimination
half-life; clearance, total plasma clearance; VdSs, apparent volume of distribution at steady state; MRT, mean residence time.
Table V Pharmacokinetic data after i.v. administration of GI147211 on day 4 of the first course
Patient Dose AUCjnf C,m... tmax ti MRT Clearance Vd,,
number (mg m-2) Day (ng ml-' h) (ng mr') (h) (h) (h) (mlmi-l m-2) (1 m-2)
1 0.3 4 6.19 4.73 0.25 4.82 4.62 808 207
2 0.3 4 6.79 4.30 0.25 2.34 4.73 736 199
3 0.3 4 7.46 5.11 0.42 3.81 5.30 670 199
Mean 6.81 4.71 0.31 3.65 4.88 738 202
4 0.6 4 11.21 7.60 0.42 3.42 4.89 892 246
5 0.6 4 15.10 8.13 0.42 3.78 5.38 662 203
6 0.6 4 15.94 9.29 0.25 4.15 6.35 6.27 224
Mean 14.08 8.34 0.36 3.78 5.54 727 224
7 1.2 4 20.59 18.66 0.25 3.02 3.06 971 163
8 1.2 4 37.83 20.03 0.42 4.07 5.62 529 167
9 1.2 4 21.10 16.21 0.42 2.70 3.47 948 182
10 1.2 4 14.84 9.62 0.42 2.20 3.96 1348 299
11 1.2 4 26.62 12.74 0.42 6.99 7.06 802 307
12 1.2 4 16.96 11.63 0.42 4.99 4.44 1179 291
Mean 22.99 14.82 0.39 3.99 4.60 963 235
13 1.5 4 26.92 20.02 0.42 4.95 5.06 929 261
14 1.5 4 29.51 23.81 0.42 3.44 2.56 847 117
15 1.5 4 30.85 25.41 0.25 4.35 3.04 810 144
16 1.5 4 34.51 32.19 0.42 5.62 4.47 724 178
17 1.5 4 24.85 21.18 0.25 5.82 5.75 1006 319
18 1.5 4 52.70 28.25 0.42 4.43 4.74 474 126
Mean 33.22 25.14 0.36 4.77 4.27 798 191
AUCinf, AUC after extrapolation to infinity; Cm,,,, maximal plasma concentration; tma, time to maximal plasma concentration; ti, elimination
half-life; clearance, total plasma clearance; VdSS, apparent volume ofdistribution at steady state; MRT, mean residence time.Phase I and pharmacological study of G1147211
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TableVI Pharmacokinetic data after i.v. administration of GI147211 on days 1 and 4 of the first course
Patient Cir Cir Cir Cir
number Day fe (mlmin'-) Day fe (mlmin1-) (mlmin'F m-2)
1 1 0.114 232 116 4 0.109 175 88
2 1 0.081 184 101 4 0.095 128 70
3 1 0.212 333 222 4 0.428 430 287
4 1 0.115 231 115 4 - - -
5 1 0.156 161 101 4 0.181 192 120
6 1 0.149 194 107 4 0.197 225 123
7 1 0.106 201 122 4 0.122 196 119
8 1 0.101 151 84 4 0.219 212 118
9 1 0.088 203 107 4 0.133 241 127
10 1 0.085 226 113 4 0.128 344 172
11 1 0.116 208 119 4 0.239 314 179
12 1 0.347 663 358 4 0.210 459 248
13 1 - - - 4 - - -
14 1 0.191 - - 4 - -
15 1 0.135 280 150 4 - - -
16 1 - - - 4 0.177 218 128
17 1 - - - 4 0.090 182 91
18 1 - - - 4 0.125 101 59
Mean 0.143 251 140 0.0175 244 138
s.d. 0.070 133 74 0.087 106 64
CV (%) 49 53 53 50 43 47
fe, fraction ofthe drug excreted unchanged; Clr, renal clearance.
development of several semisynthetic CPT analogues, of
which some are under extensive clinical investigation. This is
the first report of a clinical phase I study with GI147211.
The dose-limiting toxicity of G1147211 administered as a
30 min i.v infusion for 5 consecutive days in patients with
solid tumours was neutropenia in conjunction with thrombo-
cytopenia. The dose of 1.2 mg m-2 day-' was considered the
maximally tolerated dose. At this dose the onset of
neutropenia grade 3-4 occurred between days 10 and 19,
with a median ANC nadir of 1.29 x 109 1-' (range 0.08-5.6).
The median day of the platelet nadir and the first day of
grade 3-4 toxicity was day 15. The median number of days
to recovery was 7 (range 2-8). The recovery of neutropenia
was even more prolonged, it lasted 10 days (range 1-10).
Owing to this prolonged myelosuppression subsequent
courses had to be postponed in 6/15 courses at this dose
level of 1.2 mg m-2 day-'. At the dose of 1.5 mg m-2 day-'
the dose-limiting toxicity was reached. At this dose grade 3-
4 neutropenia already was noticed as early as day 10 (range
5-25) and lasted for 11 days (4-25) with a median ANC
nadir of 0.09 x 109 I` (range 0.01-1.7). This deep and
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prolonged recovery from neutropenia was complicated by
three septic episodes, and resulted in treatment delay in 5 of
the 15 courses given at this dose level. Although the depth,
the time of occurrence and recovery from thrombocytopenia
at this dose level was equal to the dose of 1.2 mg m-2 day-',
at this dose the thrombocytopenia was complicated in two
courses by gastrointestinal bleeding.
As only one patient was heavily pretreated (ten courses of
anthracyclin-containing chemotherapy) at the higher dose
levels, these treatment delays were not related to prior
myelosuppressive therapies. There were no indications of
cumulative myelosuppression, the pattern of myelosuppres-
sion in subsequent courses was equal (see Figure 2). The use
of haematopoietic growth factors might be helpful in
preventing infections, but will be of limited value in further
dose escalation of GI147211, since dose-limiting thrombocy-
topenia occurred in conjunction with neutropenia.
The pharmacokinetic analysis reveals moderate interpa-
tient variability. The pharmacokinetic data, obtained on days
1 and 4 of course one, demonstrate limited intrapatient
variability. There was a linear relationship between the AUC
0
U
U
U
U
.
U
0
0.5 1.0
Dose (mg m-2)
1.5 2.0
Figure 3 Relationship between the dose m-2 and the area under
the curve (AUC) of G1147211 determined on day 4 of course 1.
AUC24 (ng h-1 mF1)
Figure 4 Relationship between the AUC of GI14721 1 deter-
mined on day 4 of the first course and the per cent decrease in
AUC. The sigmoid Ema, model was applied.
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Frgwe 5 Relationship between the AUC of GI14721 1 deter-
mined on day 4 of the first course and the per cent decrease in
AUC, in minimally and heavily pretreated patients. EC50 value in
minimally pretreated patients, 18.95 (-U-). EC50 value in heavily
pretreated patients, 18.00 (-A-).
and the administered dose. A steep sigmoid relationship was
observed between the AUC on day 4 and per cent decrease
ANC, indicating that the AUC is predictive for the
myelosuppression.
In this study one short-lasting partial response was noted
in a patient with metastatic colorectal cancer. This fits with
the observations of activity of G1147211 in preclinical models
against colorectal cancer. In addition, it is of interest that we
observed a minor response in a patient with leiomyosarcoma.
In a recently reported phase H study in metastatic soft tissue
sarcoma the topoisomerase I inhibitor topotecan only showed
responses in patients with leiomyosarcoma (Eisenhauer et al.,
1994).
In phase I studies with a daily x 5 schedule of topotecan
the dose-limiting toxicity was also myelosuppression, pre-
dominantly severe neutropenia of brief duration not
necessitating treatment delays (Rowinsky et al., 1992;
Verweij et al., 1993). Thrombocytopenia mainly occurred in
prolonged continuous regimens and the myelosuppression
was not cumulative (Hochster et al., 1994). As the daily x 5
schedule appeared to be most active in early phase I studies
many different phase II studies were initiated with this
scheme. Although a randomised comparison is obviously
lacking, G1147211 seems to induce more prolonged
myelosuppression than topotecan. Presumably related to
this, in contrast to topotecan, G1147211 administration
necessitated relatively frequent delays of retreatment. These
human data therefore confirm preclinical studies in bone
marrow cultures where GI147211 was found to be more
myelotoxic than topotecan. In preclinical studies this
increased myelotoxicity of GI147211 seems to coincide with
more anti-tumour activity (Emerson et al., 1995).
The other topoisomerase I inhibitor in a well-advanced
stage of clinical development, Irinotecan (CPT-l1) induces
neutropenia in addition to diarrhoea. Diarrhoea was not
observed at all for GI147211. Unlike GI147211, which is the
active compound, CPT-ll is a prodrug. CPT-l1 has to be
converted to the active metabolite SN-38. It has been
hypothesised that the conversion in the intestinal mucosa
might be responsible for the diarrhoea. The fact that such a
conversation is not required for G1147211 may result in
relatively low intestinal mucosal drug levels as compared with
SN-38, and thereby less mucosal damage.
Preclinical data have indicated that topoisomerase I
inhibitors, like topoisomerase II inhibitors, demonstrate
more efficacy with prolonged continuous exposure (Burris et
al., 1992; Giovanella et al., 1989; Houghton et al., 1993).
Therefore, future development of GI147211 will be focused
on prolonged infusions, and the apparent bioavailability of
oral administration will be determined.
The recommended dose for phase II studies with a
daily x 5 intravenous schedule is 1.2 mg m-2 day-1 repeated
every 3 weeks. Phase H studies in various tumour types have
recently been initiated.
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